Minsheng Securities released a research report on April 25 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a recommended rating. The main reasons for the rating include: 1) Noxintol's global sales increased rapidly in the first quarter, and CDMO o
Jiuzhou Pharmaceutical (603456) 2023 Report Review: Annual Revenue and Profit Growth Slows Down, CDMO Business Achieves High-Quality Growth
Jiuzhou Pharmaceutical (603456): CDMO is tough under short-term pressure in the API business
Jiuzhou Pharmaceutical (603456): Annual revenue and profit growth slowed, CDMO business achieved high-quality growth
Southwest Securities released a research report on April 16 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a purchase rating. The main reasons for the rating include: 1) the performance was in line with expectations, and the CDMO sector achieved
Jiuzhou Pharmaceutical (603456): CDMO business is growing steadily, APIs are under pressure in the short term
Jiuzhou Pharmaceutical (603456): CDMO is growing steadily and the API business is under pressure in the short term
Jiuzhou Pharmaceutical (603456): CDMO business grows steadily and continues to lay out new businesses
Great Wall Guorui Securities released a research report on April 9 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a purchase rating. The main reasons for the rating include: 1) Profitability has increased, putting pressure on the API business; 2)
Minsheng Securities released a research report on April 9 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a recommended rating. The main reasons for the rating include: 1) the rapid expansion of CDMO business for APIs and formulations, and a stead
Jiuzhou Pharmaceutical (603456): CDMO's steady growth puts pressure on the API sector
Jiuzhou Pharmaceutical (603456) Annual Report Review Report: Revenue is basically in line with expectations. The CDMO sector maintains high growth and the project pipeline continues to be rich
Jiuzhou Pharmaceutical (603456): CDMO is resilient and waits for peak rotation
Jiuzhou Pharmaceutical (603456): Performance showed steady growth and the API business was under pressure
Jiuzhou Pharmaceutical (603456) 2023 Annual Report Review: CDMO Commercialization Revenue Steady Increase and Continues to Build Advanced Global Production Capacity
Jiuzhou Pharmaceutical (603456): Plan the long term based on the present
Jiuzhou Pharmaceutical (603456): The trend in the first half of the year continued, CDMO led growth
Jiuzhou Pharmaceutical (603456): BD strengthens its efforts and continues to improve profitability
Jiuzhou Pharmaceutical (603456) Company Information Update Report: Profitability is gradually increasing under phased pressure on the revenue side
Review of the 2023 Three-Quarter Report of Jiuzhou Pharmaceutical (603456): Continued construction of new production capacity and new business, CDMO drives medium- to long-term high-quality growth
No Data